MedicinalProductDefinition Example: medicinalproductdefinition-example-equilidem-basics

Narrative

Generated Narrative

Id : equilidem-basics

Identifier : Equilidem25

Combined Pharmaceutical Dose Form : tablet

Indication : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Legal Status Of Supply : Prescription only medicine

Classification : ATC: B01A

Ingredient :

• Equilidonium Phosphate
• Calcium Carbonate

Names

Cross References

Manufacturing/Business Operations

Example XML

<?xml version="1.0" encoding="UTF-8"?>
<MedicinalProductDefinition xmlns="http://hl7.org/fhir" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://hl7.org/fhir ../../schema/medicinalproductdefinition.xsd">
    <id value="equilidem-basics"/>
    <text>
        <status value="generated"/>
        <div xmlns="http://www.w3.org/1999/xhtml">
            <p>
                <b>
                    Generated Narrative
                </b>
            </p>
            <p>
                <b>
                    Id
                </b>
                : equilidem-basics
            </p>
            <p>
                <b>
                    Identifier
                </b>
                : Equilidem25
            </p>
            <p>
                <b>
                    Combined Pharmaceutical Dose Form
                </b>
                :
                <span title="Codes: {http://example.org.uk/fhir/dosefom tablet}">
                    tablet
                </span>
            </p>
            <p>
                <b>
                    Indication
                </b>
                : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
            </p>
            <p>
                <b>
                    Legal Status Of Supply
                </b>
                :
                <span title="Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}">
                    Prescription only medicine
                </span>
            </p>
            <p>
                <b>
                    Classification
                </b>
                :
                <span title="Codes: {http://www.whocc.no/atc/example B01A}">
                    ATC: B01A
                </span>
            </p>
            <p>
                <b>
                    Ingredient
                </b>
                :
            </p>
            <ul>
                <li>
                    <span>
                        Equilidonium Phosphate
                    </span>
                </li>
                <li>
                    <span>
                        Calcium Carbonate
                    </span>
                </li>
            </ul>
            <h3>
                Names
            </h3>
            <table class="grid">
                <tr>
                    <td>
                        -
                    </td>
                    <td>
                        <b>
                            Product Name
                        </b>
                    </td>
                </tr>
                <tr>
                    <td>
                        *
                    </td>
                    <td>
                        Equilidem 2.5 mg film-coated tablets
                    </td>
                </tr>
            </table>
            <h3>
                Cross References
            </h3>
            <table class="grid">
                <tr>
                    <td>
                        -
                    </td>
                    <td>
                        <b>
                            Product
                        </b>
                    </td>
                </tr>
                <tr>
                    <td>
                        *
                    </td>
                    <td>
                        Link to generic equivalent
                    </td>
                </tr>
            </table>
            <h3>
                Manufacturing/Business Operations
            </h3>
            <table class="grid">
                <tr>
                    <td>
                        -
                    </td>
                    <td>
                        <b>
                            Manufacturer
                        </b>
                    </td>
                </tr>
                <tr>
                    <td>
                        *
                    </td>
                    <td>
                        <span>
                            EquiliDrugCo Inc.
                        </span>
                    </td>
                </tr>
            </table>
        </div>
    </text>
    <identifier>
        <system value="http://example.org.uk/fhir/product"/>
        <value value="Equilidem25"/>
    </identifier>
    <combinedPharmaceuticalDoseForm>
        <coding>
            <system value="http://example.org.uk/fhir/dosefom"/>
            <code value="tablet"/>
        </coding>
    </combinedPharmaceuticalDoseForm>
    <indication value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."/>
    <legalStatusOfSupply>
        <coding>
            <system value="http://example.org.uk/fhir/legalstatusofsupply"/>
            <code value="POM"/>
            <display value="Prescription only medicine"/>
        </coding>
    </legalStatusOfSupply>
    <classification>
        <coding>
            <system value="http://www.whocc.no/atc/example"/>
            <code value="B01A"/>
        </coding>
    </classification>
    <ingredient>
        <text value="Equilidonium Phosphate"/>
    </ingredient>
    <ingredient>
        <text value="Calcium Carbonate"/>
    </ingredient>
    <name>
        <productName value="Equilidem 2.5 mg film-coated tablets"/>
    </name>
    <crossReference>
        <product>
            <reference>
                <reference value="MedicinalProductDefinition/genericEquilidonium"/>
            </reference>
        </product>
    </crossReference>
    <operation>
        <organization>
            <display value="EquiliDrugCo Inc."/>
            <!-- licence holder would use RegulatedAuthorization -->
        </organization>
    </operation>
</MedicinalProductDefinition>